GTHX G1 Therapeutics: Earnings per share for the last 12 months

Slow sales of Cosela and a liquidity shortage are putting pressure on the margins of G1 Therapeutics, Inc. (GTHX). The ttm YoY earnings per share trend captures the business's adaptation, where the value of 60.30 determines the status of the profitability parameter. The team is currently optimizing licensing payments while implementing CDK4/6 inhibitors to protect patients' bone marrow during chemotherapy.
GTHX (G1 Pharma): analytical breakdowns and indicator data

The indicator is calculated as the percentage change in net earnings per share over a rolling 12-month period, reflecting capital sensitivity to operating results. This metric determines the actual speed of business recovery and the pace of overcoming crisis phases. For G1 Therapeutics, Inc. (GTHX), this serves as a marker for the commercialization efficiency of CDK4/6 inhibitors. The relative YoY EPS growth over the last 12 months demonstrates how successfully the patient immunity protection strategy is being converted into shareholder value.